Versor Investments LP Invests $1.09 Million in Charles River Laboratories International, Inc. (NYSE:CRL)

Versor Investments LP bought a new position in Charles River Laboratories International, Inc. (NYSE:CRL) during the fourth quarter, HoldingsChannel.com reports. The fund bought 5,927 shares of the medical research company’s stock, valued at approximately $1,094,000.

A number of other large investors have also recently made changes to their positions in the business. Wellington Management Group LLP grew its holdings in Charles River Laboratories International by 135,927.9% during the 3rd quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the last quarter. Mizuho Securities USA LLC lifted its position in Charles River Laboratories International by 2,336.4% during the third quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock valued at $19,081,000 after acquiring an additional 92,895 shares during the last quarter. Premier Fund Managers Ltd lifted its position in Charles River Laboratories International by 56.3% during the third quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company’s stock valued at $49,573,000 after acquiring an additional 90,000 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after acquiring an additional 85,759 shares during the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in Charles River Laboratories International during the 4th quarter valued at approximately $10,768,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Stock Performance

Shares of NYSE CRL opened at $164.91 on Friday. The company’s fifty day moving average price is $171.35 and its 200 day moving average price is $187.25. Charles River Laboratories International, Inc. has a 1 year low of $150.79 and a 1 year high of $275.00. The company has a market capitalization of $8.43 billion, a PE ratio of 1,099.39, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.63 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company’s revenue was down 1.1% compared to the same quarter last year. During the same period last year, the firm posted $2.46 earnings per share. On average, research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of recent analyst reports. Evercore ISI upped their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research note on Thursday, November 7th. William Blair lowered shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. TD Cowen upped their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Finally, Bank of America cut their price objective on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $195.71.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, COO Birgit Girshick purchased 1,514 shares of the firm’s stock in a transaction dated Thursday, February 20th. The shares were purchased at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares in the company, valued at approximately $9,064,198.54. This represents a 2.83 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).